Jan 11, 2024 / 05:45PM GMT
Brian Cheng JPMorgan Chase&Co.-Analyst
Good morning. Thanks for joining us for another session at the 42nd JPMorgan Healthcare conference. I'm Brian Cheng, I'm one of the senior biotech analysts here. I'm joined by my associate [Shawn Kim] who's in the audience today.
On stage, we have the whole team from BioAtla, which is also in the audience. So we're going to start -- kick off with a fireside chat style to kind of walk through your entire portfolio and get the latest and greatest. Maybe it will be great to kind of get a recap of the latest development.
December have been a particularly busy time for you across a number of assets in your portfolio. So maybe, Jay, maybe you can kick us off with just you know what we got in 2023. What were the key milestones that you achieved back last year, specifically around December. And as we look into 2024, what are the key goals across each of the program.
Jay Short - Bioatla Inc - Chairman of the Board, Chief Executive Officer, Co-Founder
Okay. Well, thanks for inviting us
Bioatla Inc at JPMorgan Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers